Angiogenesis, angiogenic factor expression and hematological malignancies

Domenico Ribatti, Angelo Vacca, Giuseppe De Falco, Aldo Roccaro, Luisa Roncali, Franco Dammacco

Research output: Contribution to journalArticle

Abstract

Solid tumor growth consists of an avascular and a subsequent vascular phase. Several studies have now shown that, as in solid tumors, angiogenesis also plays a critical role in the progression of hematological malignancies. Monoclonal gammopathy of undetermined significance (MGUS) and non-active to active multiple myeloma (MM) progress when plasma cells induce angiogenesis and this in turn promotes progression. The increased bone marrow neovascularization, increased angiogenic and proteolytic potential of plasma cells may explain the frequent occurrence of extramedullary localization in MM. As observed in active MM, enhanced bone marrow neovascularization is apparent in acute untreated lymphoblastic leukemia. In B-cell non-Hodgkin's lymphomas, angiogenesis is significantly enhanced in relation to progression. Angiostatic molecules, such as thalidomide, could also be considered for the clinical management of hematological tumors.

Original languageEnglish
Pages (from-to)4333-4339
Number of pages7
JournalAnticancer Research
Volume21
Issue number6 B
Publication statusPublished - 2001

    Fingerprint

Keywords

  • Angiogenesis
  • Growth factors
  • Hematological tumors
  • Hematopoiesis

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Ribatti, D., Vacca, A., De Falco, G., Roccaro, A., Roncali, L., & Dammacco, F. (2001). Angiogenesis, angiogenic factor expression and hematological malignancies. Anticancer Research, 21(6 B), 4333-4339.